TABLE 3.
Predictive impact of biomarkers in NSCLC patients treated with complete resection with or without ACT
| First author [ref.] | Subjects n | Treatment | Stage | Method | Biomarker | Biomarker expression | Disease-free survival | Overall survival | ||||
| Survival | p-value | Survival | p-value | |||||||||
| Univariate | Multivariate | Univariate | Multivariate | |||||||||
| Bepler [51] | 784 | ACT (CDDP-based) or OP# | I–III | IHC | ERCC1 | Low (ACT versus OP) | HR: 0.76 (0.59–0.99) | 0.04 | NA | HR: 0.73 (0.55–0.96) | 0.02 | NA |
| High (ACT versus OP) | HR: 0.97 (0.72–1.30) | 0.82 | NA | HR: 1.01 (0.74–1.38) | 0.94 | NA | ||||||
| Olaussen [18] | 761 | ACT (CDDP- based) or OP# | I–III | IHC | ERCC1 | Low (ACT versus OP) | NA | 0.001 | NA | 56 versus 42 months | 0.002 | NA |
| High (ACT versus OP) | NA | NA | 50 versus 55 months | 0.40 | NA | |||||||
| Pierceall [21] | 426 only SCC | ACT (CDDP- based) or OP# | I–III | IHC | ERCC1 | High (ACT versus OP) | HR: 2.02 (1.19–3.43) | NA | 0.01 | HR: 1.67 (0.97–2.87) | NA | 0.06 |
| Low (ACT versus OP) | NA | NA | NA | NA | ||||||||
| Tsao [23] | 253 | ACT (CDDP + NVB) or OP# | IB–II | IHC | p53 | Positive (ACT versus OP) | NA | NA | NA | HR: 0.54 (0.32–0.92) | 0.02 | 0.05 |
| Negative (ACT versus OP) | NA | NA | NA | HR: 1.4 (0.78–2.52) | 0.26 | NA | ||||||
| Pierceall [21] | 426 only SCC | ACT (CDDP- based) or OP# | I–III | IHC | p53 | High (ACT versus OP) | HR: 1.72 (1.03–2.88) | NA | 0.04 | HR: 1.81 (1.07–3.06) | NA | 0.03 |
| Low (ACT versus OP) | NA | NA | NA | NA | ||||||||
| Pierceall [21] | 426 only SCC | ACT (CDDP- based) or OP# | I–III | IHC | MSH2 | High (ACT versus OP) | HR: 1.72 (1.03–2.87) | NA | 0.04 | HR: 1.37 (0.82–2.30) | NA | 0.24 |
| Low (ACT versus OP) | NA | NA | NA | NA | ||||||||
| Kamal [25] | 673 | ACT (CDDP- based) or OP# | I–III | IHC | MSH2 | Low (ACT versus OP) | NA | NA | NA | HR: 0.76 (0.59–0.97) | 0.03 | NA |
| High (ACT versus OP) | NA | NA | NA | HR: 1.12 (0.81–1.55) | 0.48 | NA | ||||||
| Kamal [25] | 673 | ACT (CDDP- based) or OP# | I–III | IHC | ERCC1 + MSH2 | Low–low (ACT versus OP) | NA | NA | NA | HR: 0.65 (0.47–0.91) | 0.01 | NA |
| High–high (ACT versus OP) | NA | NA | NA | HR: 1.32 (0.88–1.99) | 0.19 | NA | ||||||
| Kamal [25] | 673 | ACT (CDDP- based) or OP# | I–III | IHC | p27 (kip1) +MSH2 | Low–low (ACT versus OP) | NA | NA | NA | HR: 0.65 (0.46–0.93) | 0.01 | NA |
| High–high (ACT versus OP) | NA | NA | NA | HR: 1.31 (0.85–2.01) | 0.22 | NA | ||||||
| Filipits [52] | 778 | ACT (CDDP- based) or OP# | I–III | IHC | p27 (kip1) | Negative (ACT versus OP) | HR: 0.71 (0.54–0.94) | 0.02 | NA | HR: 0.66 (0.5–0.88) | 0.006 | NA |
| Positive (ACT versus OP) | NA | NA | HR: 1.09 (0.82–1.45) | 0.54 | NA | |||||||
| Sève [14] | 265 | ACT (CDDP + NVB) or OP# | IB–II | IHC | TUBB3 | High (ACT versus OP) | HR: 0.45 (0.27–0.75) | 0.002 | NA | HR: 0.64 (0.39–1.04) | 0.07 | NA |
| Low (ACT versus OP) | HR: 0.78 (0.44–1.37) | 0.4 | NA | HR: 1.00 (0.57–1.75) | 0.99 | NA | ||||||
| Pierceall [21] | 426 only SCC | ACT (CDDP- based) or OP# | I–III | IHC | PARP1 | High (ACT versus OP) | HR: 1.74 (1.04–2.91) | NA | 0.04 | HR: 1.63 (0.96–2.75) | NA | 0.07 |
| Low (ACT versus OP) | NA | NA | NA | NA | ||||||||
| Pierceall [21] | 426 only SCC | ACT (CDDP- based) or OP# | I–III | IHC | ATM | High (ACT versus OP) | HR: 2.08 (1.24–3.49) | NA | 0.005 | HR: 1.82 (1.07–3.07) | NA | 0.03 |
| Low (ACT versus OP) | NA | NA | NA | NA | ||||||||
Survival data are presented as hazard ratio (HR) (95% CI) or time. NSCLC: nonsmall cell lung cancer; ACT: adjuvant chemotherapy; CDDP: cisplatin; OP: complete surgery only; IHC: immunohistochemistry; ERCC1: excision repair cross-complementation group 1; NA: not available; SCC: squamous cell carcinoma; NVB: vinorelbine; MSH2: MutS homologue 2; p27 (kip1): cyclin-dependent kinase inhibitor 1B; TUBB3: β-tubulin class III; PARP: poly (ADP-ribose) polymerase; ATM: ataxia telangiectasia mutated. #: randomised trial, ACT group and OP group (control group).